Drug Trial Radar · NCT06716970
QR12000 Compound Tablets in Patients with Moderate to Severe Essential Hypertension
Last checked: Nov 20, 2026Latest source record: Dec 6, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
810
Planned (sponsor's estimate)
Start
Dec 30, 2024
Primary completion
Apr 30, 2026
Study completion Feb 28, 2027
Sponsor
- Lead sponsor
- Wuhan Createrna Science and Technology Co., LtdIndustry
- Sponsor type
- Industry
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to evaluate the efficacy and safety of QR12000 75mg, QR12000 150mg and Sacubitril/valsartan 200mg in patients with moderate to severe essential hypertension.
Conditions
- Essential Hypertension
Interventions
QR12000 75mgDrug
QR12000 75mg QD
QR12000 75mg placeboDrug
Matching placebo of QR12000 75mg QD
QR12000 150mgDrug
QR12000 150mg QD
QR12000 150mg placeboDrug
Matching placebo of QR12000 150mg QD
Sacubitril/valsartan 200mgDrug
Sacubitril/valsartan 200mg QD
Sacubitril/valsartan 200mg placeboDrug
Matching placebo of Sacubitril/valsartan 200mg QD
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP)Time frame: Baseline and week 8
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.